Could Halozyme Therapeutics, Inc. (HALO) Lose Strenght? The Stock Increases A Lot Today

February 21, 2018 - By Marguerite Chambers

Investors sentiment decreased to 1.26 in Q3 2017. Its down 0.76, from 2.02 in 2017Q2. It dived, as 14 investors sold Halozyme Therapeutics, Inc. shares while 44 reduced holdings. 18 funds opened positions while 55 raised stakes. 118.53 million shares or 0.58% less from 119.22 million shares in 2017Q2 were reported.
323,388 are held by Wells Fargo & Company Mn. Tower Capital Ltd Liability Co (Trc) stated it has 13,989 shares or 0.02% of all its holdings. Commonwealth Equity Inc accumulated 63,846 shares. 3.68M are owned by State Street. 23,187 are held by Pacad. Parametric Portfolio Associates Llc stated it has 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Cornerstone Cap Mngmt Ltd Liability Com invested 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Ubs Asset Mgmt Americas has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 78,268 shares. Tudor Investment Et Al owns 18,765 shares or 0.01% of their US portfolio. Senzar Asset Limited Company stated it has 16.24% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Torray reported 29,945 shares or 0.05% of all its holdings. Nj State Employees Deferred Compensation Plan stated it has 0.16% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Vanguard invested in 9.99 million shares or 0.01% of the stock. 9,416 were accumulated by Ameritas Prns Inc. Fmr Ltd Limited Liability Company holds 4.97 million shares.

The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a huge mover today! The stock increased 4.71% or $0.87 during the last trading session, reaching $19.35. About 1.55M shares traded or 25.36% up from the average. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since February 21, 2017 and is uptrending. It has outperformed by 28.19% the S&P500.
The move comes after 5 months positive chart setup for the $2.73 billion company. It was reported on Feb, 21 by Barchart.com. We have $19.93 PT which if reached, will make NASDAQ:HALO worth $81.87M more.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 9 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Halozyme Therapeutics had 21 analyst reports since August 11, 2015 according to SRatingsIntel. Deutsche Bank initiated Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Thursday, November 3 with “Buy” rating. Canaccord Genuity maintained the shares of HALO in report on Wednesday, July 26 with “Buy” rating. On Wednesday, November 18 the stock rating was initiated by Citigroup with “Buy”. The firm earned “Overweight” rating on Wednesday, February 24 by Barclays Capital. Wells Fargo initiated Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Friday, December 4 with “Outperform” rating. Piper Jaffray maintained it with “Overweight” rating and $18 target in Friday, September 16 report. JMP Securities maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Tuesday, August 11 with “Market Outperform” rating. The company was maintained on Wednesday, November 8 by BMO Capital Markets. The firm earned “Neutral” rating on Friday, January 6 by Citigroup. Piper Jaffray maintained the shares of HALO in report on Thursday, September 14 with “Buy” rating.

Another recent and important Halozyme Therapeutics, Inc. (NASDAQ:HALO) news was published by Prnewswire.com which published an article titled: “Halozyme Reports Fourth Quarter And Full-Year 2017 Results” on February 20, 2018.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.73 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It currently has negative earnings. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.